RenovoRx, a biopharmaceutical company focused on novel targeted cancer therapies, announced that the Northwell Health Cancer Institute (NHCI) in New Hyde Park, NY, is now enrolling patients in its Phase III TIGeR-PaC clinical trial. This pivotal trial is evaluating the company's RenovoCath delivery system in conjunction with gemcitabine for the treatment of locally advanced pancreatic cancer (LAPC).
The TIGeR-PaC trial is a randomized, controlled, multi-center study designed to assess the safety and efficacy of RenovoCath's intra-arterial delivery of gemcitabine, compared to systemic chemotherapy, in patients with LAPC. The primary endpoint of the trial is overall survival. Secondary endpoints include progression-free survival, objective response rate, and quality of life.
Pancreatic cancer remains a significant challenge in oncology, with LAPC representing a particularly difficult-to-treat stage of the disease. Current treatment options for LAPC often involve systemic chemotherapy, which can be associated with significant side effects and limited efficacy. The TIGeR-PaC trial aims to address this unmet need by delivering chemotherapy directly to the tumor site, potentially improving treatment outcomes while minimizing systemic toxicity.
NHCI joins a growing network of clinical sites across the United States participating in the TIGeR-PaC trial. This expansion aims to accelerate patient enrollment and facilitate the timely completion of this important study. The results of the TIGeR-PaC trial could potentially lead to a new standard of care for patients with LAPC.
